Filing Details

Accession Number:
0000904454-18-000631
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-02 18:58:24
Reporting Period:
2018-09-24
Accepted Time:
2018-10-02 18:58:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1526119 Verastem Inc. VSTM Pharmaceutical Preparations (2834) 273269467
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1563202 Dan Paterson C/O Verastem, Inc.
117 Kendrick Street, Suite 500
Needham MA 02494
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-09-28 3,000 $7.00 23,286 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2018-09-24 30,000 $0.00 30,000 $2.97
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,000 2018-09-24 2028-01-05 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 54,446 Indirect By The Paterson 1996 Living Trust
Footnotes
  1. The Reporting Person is the trustee of The Paterson 1996 Living Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  2. On January 5, 2018, the Reporting Person was granted an option to purchase 75,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 15,000 shares. 40% of the performance criteria was met on September 24, 2018, resulting in vesting of the option as to 30,000 shares.